Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study - Top-Institutions - MDSpire

Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study

  • By

  • Wenwen Cui

  • Lihang Xing

  • Zhenzhen Li

  • Xinjun Li

  • Junzhi Li

  • July 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Tianjin Medical University Cancer Institute and Hospital
    Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin

    Key Differentiators

    • Oncology

  • #2

    Binzhou People’s Hospital
    Binzhou People’s Hospital

    Binzhou, Shandong

    Key Differentiators

    • Oncology

  • #3

    Shandong Provincial Maternal and Child Health Hospital
    Shandong Provincial Maternal and Child Health Hospital

    Jinan, Shandong

    Key Differentiators

    • Oncology

  • #4

    Cancer Genome Atlas
    Cancer Genome Atlas

    N/A, N/A

    Key Differentiators

    • Oncology

  • #5

    World Health Organization
    World Health Organization

    Geneva, Switzerland

    Key Differentiators

    • Public Health

Original Source(s)

Clinicopathological, proliferative, molecular, and prognostic characteristics of differentiated high-grade thyroid carcinoma: a multicenter retrospective study

  • by Wenwen Cui, Lihang Xing, Zhenzhen Li, Xinjun Li, Junzhi Li

  • July 8, 2026

Related Content

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

Hope is everything – an hermeneutic phenomenological study on the lived experiences of individuals with adrenocortical carcinoma

This Week's CGT News: First Treg Therapy Approved

First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma

  • July 7, 2026

  • 6 min